<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112571">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01836666</url>
  </required_header>
  <id_info>
    <org_study_id>SE-Dnr-2012-446-31M-1</org_study_id>
    <nct_id>NCT01836666</nct_id>
  </id_info>
  <brief_title>Effects on Health Related Quality of Life Among Patients With Chronic Pain by Interventional Pain Management</brief_title>
  <official_title>Effects on Health Related Quality of Life Among Patients With Chronic Pain by Interventional Pain Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eques Indolor AB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eques Indolor AB</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      How are the health related quality of life among patients with chronic pain effected by
      interventional pain managment?

      Hypothesis:

      Health related quality of life can be improved by interventional pain management both among
      patients with localizable pain focuses and among patients among whom no pain focuses can be
      found.

      Method:

      Health related quality of life using EQ-5D and EQ-VAS is registered at first visit, at the
      time of treatment for pain focuses an during the following 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Ecologic or Community, Time Perspective: Prospective</study_design>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>EQ-VAS</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>EQ-VAS is measured at first visit, at time for treatment and 3, 6 and 12 months after treatment. EQ-VAS gives a value of quality of life, and mainly used to verify the results achieved from EQ-5D since it is not possible to calculate QALY from EQ-VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>EQ-5D is assessed at first visit, at time for treatment and 3, 6 and 12 months after treatment. Quality of life is calculated from EQ-5D using the TTO-valuated UK value sets. This value can also be used for calculation of QALY, Quality adjusted life years.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Chronic Pain</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred to a specialized interventional pain management clinic in northen sweden
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Hambraeus, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Johan Hambraeus, MD</last_name>
    <phone>+46706293798</phone>
    <email>johan@smartkliniken.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Smärtkliniken i Umeå</name>
      <address>
        <city>Umeå</city>
        <zip>90325</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Hambraeus, MD</last_name>
      <phone>+46706293798</phone>
      <email>johan@smartkliniken.eu</email>
    </contact>
    <contact_backup>
      <last_name>Eva Umaerus, RN</last_name>
      <phone>+4690186018</phone>
    </contact_backup>
    <investigator>
      <last_name>Johan Hambraeus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fredrik Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kjerstin Segerstedt Hambraeus, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 17, 2013</lastchanged_date>
  <firstreceived_date>April 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
